The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RG7388 activates p53 to inhibit hematological tumors345 and solid tumors,346,347 but long-term administration may lead to p53 mutations and drug resistance.348,349”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [346]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · cited 1×
“p53 inhibits MDM2 by binding to the N-terminal activation domain, and in turn, MDM2 regulates p53 through ubiquitinmediated protein degradation.(9,10) In human cancers, studies have shown that MDM2 was frequently altered, and over-expressed by gene amplification in breast cancer, sarcomas, melanoma, and ovarian.”
BackgroundDiscovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595
Translating p53 into the clinic
Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381
Targeting the p53–MDM2 interaction to treat cancer
Klein, C., & Vassilev, L. T. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602164 · Cited by 204
Higgins, B., Glenn, K., Walz, A., Tovar, C., Filipovic, Z., Hussain, S., Lee, E., Kolinsky, K., Tannu, S., Adames, V., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0460 · Cited by 63
Research works printed but not linked: 24
- 10.1186/1476-4598-6-1 · doi:10.1186/1476-4598-6-1
- 10.2174/1389557517666170717125821 · DOI
- 10.1097/CAD.0b013e328337160e · doi:10.1097/cad.0b013e328337160e
- 10.1016/j.radonc.2011.12.028 · doi:10.1016/j.radonc.2011.12.028
- 10.1016/s1470-2045(11)70303-5 · DOI · Paper page
- 10.1200/jco.2005.02.147 · DOI · Paper page
- 10.1007/BF01535205 · DOI · Paper page
- 10.1016/S0022-2836(02)00852-5 · DOI · Paper page
- 10.1038/387296a0 · DOI · Paper page
- Baliou E, 2016, J Buon, 21, 1099
- 10.1186/s13045-017-0500-5 · DOI · Paper page
- 10.1038/bjc.2017.433 · DOI
- Joyce C, 2018, StatPearls
- 10.1073/pnas.1431692100 · DOI · Paper page
- 10.1038/nrm2147 · DOI · Paper page
- 10.1073/pnas.89.14.6516 · DOI
- 10.1097/00005537-200211000-00019 · doi:10.1097/00005537-200211000-00019
- 10.1097/md.0000000000011978 · doi:10.1097/md.0000000000011978
- 10.4161/cc.3.4.801 · DOI · Paper page
- 10.1158/0008-5472.can-05-4399 · DOI · Paper page
- 10.1016/j.gendis.2018.07.002 · DOI
- 10.18632/oncotarget.9499 · DOI
- 10.1158/1078-0432.ccr-17-0668 · DOI
- 10.18632/oncotarget.19266 · DOI
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Metadata
- Authors
- Fan, X., Wang, Y., Song, J., Wu, H., Yang, M., Lu, L., Weng, X., Liu, L., & Nie, G.
- Affiliations
- Department of Otolaryngology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, PR China
- Department of Pathology, Shenzhen Second People’s Hospital, Shenzhen, PR China
- Department of Obstetrics, Shenzhen Second People’s Hospital, Shenzhen, PR China
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2019-07-16
- Volume
- 20
- Issue
- 10
- Pages
- 1328-1336
- ISSN
- 1538-4047
- 1555-8576
- Cited by
- 32
- References
- 5
- Language
- en
- Funders
- China Postdoctoral Science Foundation (2018M633229)
- Natural Science Foundation of Guangdong Province (2018A0303130295, 2018A030310665)
- Shenzhen Science and Technology Innovation Committee (JCYJ20170306091657539, GJHZ20170313172439851, ZDSYS201707281114196, JCYJ20170302165727389, JCYJ20170306091452714)
- Consejo Estatal de Ciencia, Tecnología e Innovación (MX) (JCYJ20170413162242627)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma. https://app.cochat.ai/papers/10.1080/15384047.2019.1638677
- The paper
- Fan, X., Wang, Y., Song, J., Wu, H., Yang, M., Lu, L., Weng, X., Liu, L., & Nie, G. (2019). MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma. Cancer Biology & Therapy. https://doi.org/10.1080/15384047.2019.1638677
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.